The tumor stroma is an integral part of the tumor that becomes reprogrammed by unknown mechanisms to co-evolve with epithelial tumor cells and provide an environment conducive for tumor initiation and progression. However, whether alterations in the stroma contribute to the diversity, heterogeneity and plasticity of breast cancer phenotypes, and to the therapeutic responses and clinical outcome in patients is unknown. Our combined preliminary data using mouse models suggests that the Pten and p53 pathways play key and distinct tumor suppressor roles in stromal fibroblasts of the mammary gland. In parallel, gene expression profiling of human breast tumor stroma has identified distinct subclasses of stroma that can predict patient outcomes independent of established clinical variables and the established molecular tumor subtypes. Comparison of gene signatures from Pten-null and p53-null mouse fibroblasts to human tumor stroma signatures show that the mouse signatures are present in human tumor stroma, can help stratify stromal subclasses associated with predominantly non-luminal breast cancers, and can predict poor patient outcome. The overall hypothesis for this proposal is that defining the pathways that regulate tumor-stroma crosstalk will lead to better stratification of breast cancer patients, better informed application of current therapies to patients that are most likely to benefit from them, and to the development of new therapies that target the tumor-stromal interactions uncovered by our studies. Our combined mouse-human approach will utilize novel genetic, genomic and proteomic technologies developed by our groups to 1) expose how stromal cells use integrated transcriptional programs to communicate between themselves and with tumor cells during the initial stages of malignancy, and 2) to identify stromal expression profiles that can better stratify breast cancer patients, predict clinical outcome and be used for serum-based diagnostics. The synergistic efforts between the three projects, utilizing a combined mouse-human approach, is only effective because of the unique expertise and technologies provided by each group with a focus on the single task of understanding the tumor-stroma dialogue in human breast cancer, and in translating such basic information to stratify stroma subclasses, predict clinical outcome and develop specific treatments for individual patients.

Public Health Relevance

Breast cancer remains the second leading cause of cancer death in women, with 40,000 deaths in the US and over 500,000 deaths worldwide, in 2010 alone. This Program focuses on how the stroma of breast tumors promotes growth and spread of breast cancer, using human samples and mouse models. Our studies will provide a significant advance in our basic knowledge of tumor-stroma interactions, and provide the tools to better stratify breast cancer patients so that treatments can be tailored to individual patients.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Research Program Projects (P01)
Project #
Application #
Study Section
Special Emphasis Panel (ZCA1-RPRB-O (O1))
Program Officer
Snyderwine, Elizabeth G
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Ohio State University
Schools of Medicine
United States
Zip Code
Sizemore, Steven T; Mohammad, Rahman; Sizemore, Gina M et al. (2018) Synthetic Lethality of PARP Inhibition and Ionizing Radiation is p53-dependent. Mol Cancer Res 16:1092-1102
Pitarresi, Jason R; Liu, Xin; Avendano, Alex et al. (2018) Disruption of stromal hedgehog signaling initiates RNF5-mediated proteasomal degradation of PTEN and accelerates pancreatic tumor growth. Life Sci Alliance 1:e201800190
Ahirwar, Dinesh K; Nasser, Mohd W; Ouseph, Madhu M et al. (2018) Fibroblast-derived CXCL12 promotes breast cancer metastasis by facilitating tumor cell intravasation. Oncogene 37:4428-4442
Rudolph, M; Sizemore, S T; Lu, Y et al. (2018) A hedgehog pathway-dependent gene signature is associated with poor clinical outcomes in Luminal A breast cancer. Breast Cancer Res Treat 169:457-467
Sizemore, Gina M; Balakrishnan, Subhasree; Thies, Katie A et al. (2018) Stromal PTEN determines mammary epithelial response to radiotherapy. Nat Commun 9:2783
Victor, Aaron R; Nalin, Ansel P; Dong, Wenjuan et al. (2017) IL-18 Drives ILC3 Proliferation and Promotes IL-22 Production via NF-?B. J Immunol 199:2333-2342
Liu, Huayang; Dowdle, James A; Khurshid, Safiya et al. (2017) Discovery of Stromal Regulatory Networks that Suppress Ras-Sensitized Epithelial Cell Proliferation. Dev Cell 41:392-407.e6
Tang, Xing; Srivastava, Arunima; Liu, Huayang et al. (2017) annoPeak: a web application to annotate and visualize peaks from ChIP-seq/ChIP-exo-seq. Bioinformatics 33:1570-1571
Sizemore, G M; Balakrishnan, S; Hammer, A M et al. (2017) Stromal PTEN inhibits the expansion of mammary epithelial stem cells through Jagged-1. Oncogene 36:2297-2308
Hammer, Anisha M; Sizemore, Gina M; Shukla, Vasudha C et al. (2017) Stromal PDGFR-? Activation Enhances Matrix Stiffness, Impedes Mammary Ductal Development, and Accelerates Tumor Growth. Neoplasia 19:496-508

Showing the most recent 10 out of 89 publications